

Natalie Prinzi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5392525/publications.pdf>

Version: 2024-02-01

40
papers

808
citations

516681

16
h-index

526264

27
g-index

40
all docs

40
docs citations

40
times ranked

1637
citing authors

#	ARTICLE	IF	CITATIONS
1	Targeting the PI3K/AKT/mTOR pathway in biliary tract cancers: A review of current evidences and future perspectives. <i>Cancer Treatment Reviews</i> , 2019, 72, 45-55.	7.7	82
2	Comparative Effectiveness of Gemcitabine plus Nab-Paclitaxel and FOLFIRINOX in the First-Line Setting of Metastatic Pancreatic Cancer: A Systematic Review and Meta-Analysis. <i>Cancers</i> , 2019, 11, 484.	3.7	79
3	Correlation between MGMT promoter methylation and response to temozolomide-based therapy in neuroendocrine neoplasms: an observational retrospective multicenter study. <i>Endocrine</i> , 2018, 60, 490-498.	2.3	59
4	Metformin Use Is Associated With Longer Progression-Free Survival of Patients With Diabetes and Pancreatic Neuroendocrine Tumors Receiving Everolimus and/or Somatostatin Analogues. <i>Gastroenterology</i> , 2018, 155, 479-489.e7.	1.3	54
5	Adjuvant radiotherapy for Merkel cell carcinoma: A systematic review and meta-analysis. <i>Radiotherapy and Oncology</i> , 2019, 134, 211-219.	0.6	44
6	Prevalence of breast cancer in thyroid diseases: results of a cross-sectional study of 3,921 patients. <i>Breast Cancer Research and Treatment</i> , 2014, 144, 683-688.	2.5	42
7	Grey-Scale Analysis Improves the Ultrasonographic Evaluation of Thyroid Nodules. <i>Medicine (United Tj ETQq1 1 0.784314 rgBT /Over</i>	1.0	40
8	In papillary thyroid carcinoma $\langle scp \rangle$ BRAF $\langle /scp \rangle$ ^{V600E} is associated with increased expression of the urokinase plasminogen activator \hat{e} and its cognate receptor, but not with disease-free interval. <i>Clinical Endocrinology</i> , 2012, 77, 780-786.	2.4	38
9	Breast cancer metastatic to the pituitary gland: a case report. <i>World Journal of Surgical Oncology</i> , 2012, 10, 137.	1.9	29
10	Association of Thyroid Diseases with Primary Extra-Thyroidal Malignancies in Women: Results of a Cross-Sectional Study of 6,386 Patients. <i>PLoS ONE</i> , 2015, 10, e0122958.	2.5	29
11	Effects of selective inhibitors of Aurora kinases on anaplastic thyroid carcinoma cell lines. <i>Endocrine-Related Cancer</i> , 2014, 21, 797-811.	3.1	28
12	Deregulated Expression of Aurora Kinases Is Not a Prognostic Biomarker in Papillary Thyroid Cancer Patients. <i>PLoS ONE</i> , 2015, 10, e0121514.	2.5	27
13	Fertility drugs, reproductive strategies and ovarian cancer risk. <i>Journal of Ovarian Research</i> , 2014, 7, 51.	3.0	23
14	A classification prognostic score to predict OS in stage IV well-differentiated neuroendocrine tumors. <i>Endocrine-Related Cancer</i> , 2018, 25, 607-618.	3.1	18
15	Emerging molecular markers for the prognosis of differentiated thyroid cancer patients. <i>International Journal of Surgery</i> , 2014, 12, S52-S56.	2.7	17
16	Recent Advances in the Management of Typical and Atypical Lung Carcinoids. <i>Clinical Lung Cancer</i> , 2021, 22, 161-169.	2.6	17
17	Peptide receptor radionuclide therapy: focus on bronchial neuroendocrine tumors. <i>Tumor Biology</i> , 2016, 37, 12991-13003.	1.8	16
18	Systemic Treatment of Patients With Gastrointestinal Cancers During the COVID-19 Outbreak: COVID-19-adapted Recommendations of the National Cancer Institute of Milan. <i>Clinical Colorectal Cancer</i> , 2020, 19, 156-164.	2.3	16

#	ARTICLE	IF	CITATIONS
19	Prognostic impact of tumour burden in stage IV neuroendocrine neoplasia: A comparison between pancreatic and gastrointestinal localizations. <i>Pancreatology</i> , 2019, 19, 1067-1073.	1.1	15
20	The Role of Mesothelin as a Diagnostic and Therapeutic Target in Pancreatic Ductal Adenocarcinoma: A Comprehensive Review. <i>Targeted Oncology</i> , 2018, 13, 333-351.	3.6	14
21	Beyond Traditional Morphological Characterization of Lung Neuroendocrine Neoplasms: In Silico Study of Next-Generation Sequencing Mutations Analysis across the Four World Health Organization Defined Groups. <i>Cancers</i> , 2020, 12, 2753.	3.7	13
22	Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches. <i>Targeted Oncology</i> , 2018, 13, 567-582.	3.6	12
23	Consumption of iodized salt may not represent a reliable indicator of iodine adequacy: Evidence from a cross-sectional study on schoolchildren living in an urban area of central Italy. <i>Nutrition</i> , 2016, 32, 662-666.	2.4	11
24	Differential Diagnosis and Management of Diarrhea in Patients with Neuroendocrine Tumors. <i>Journal of Clinical Medicine</i> , 2020, 9, 2468.	2.4	11
25	Correlation between fertility drugs use and malignant melanoma incidence: the state of the art. <i>Tumor Biology</i> , 2014, 35, 8415-8424.	1.8	10
26	Entering the third decade of experience with octreotide LAR in neuroendocrine tumors: A review of current knowledge. <i>Tumori</i> , 2019, 105, 113-120.	1.1	9
27	Impact of Diabetes and Metformin Use on Enteropancreatic Neuroendocrine Tumors: Post Hoc Analysis of the CLARINET Study. <i>Cancers</i> , 2022, 14, 69.	3.7	9
28	Preclinical testing of selective Aurora kinase inhibitors on a medullary thyroid carcinoma-derived cell line. <i>Endocrine</i> , 2016, 52, 287-295.	2.3	8
29	The potential role of metformin in the treatment of patients with pancreatic neuroendocrine tumors: a review of preclinical to clinical evidence. <i>Therapeutic Advances in Gastroenterology</i> , 2020, 13, 175628482092727.	3.2	8
30	Subcutaneous metastases from colon cancer: a case report. <i>Journal of Medical Case Reports</i> , 2012, 6, 212.	0.8	7
31	Rationale and protocol of MetNET-2 trial: Lanreotide Autogel plus metformin in advanced gastrointestinal or lung neuroendocrine tumors. <i>Future Oncology</i> , 2017, 13, 1677-1683.	2.4	5
32	Primary Cerebellar Neuroendocrine Tumors: Chimeras or Real Entities A Case Report with a 6-Year Follow-Up. <i>Case Reports in Oncology</i> , 2016, 9, 432-439.	0.7	4
33	Update on medical treatment of small intestinal neuroendocrine tumors. <i>Expert Review of Anticancer Therapy</i> , 2016, 16, 969-976.	2.4	4
34	Metastatic pheochromocytomas and paragangliomas: where are we?. <i>Tumori</i> , 2022, 108, 526-540.	1.1	4
35	Somatostatin analogs in association with peptide receptor radionuclide therapy in advanced well-differentiated NETs. <i>Future Oncology</i> , 2019, 15, 3015-3024.	2.4	3
36	Effects of low-dose aspirin on clinical outcome and disease progression in patients with gastroenteropancreatic neuroendocrine neoplasm. <i>Scandinavian Journal of Gastroenterology</i> , 2019, 54, 1111-1117.	1.5	1

#	ARTICLE	IF	CITATIONS
37	NETs of the Lung. , 2021, , 163-178.		1
38	Thyroid Autoantibodies and Breast Cancer. Asian Pacific Journal of Cancer Prevention, 2015, 15, 10999-10999.	1.2	1
39	The role of modulation of somatostatin analogues (SSAs) in association to peptide receptor radionuclide therapy (PRRT) after SSAs progression disease (PD) in advanced well-differentiated (WD) entero-pancreatic neuroendocrine tumours (EP-NETs). Annals of Oncology, 2018, 29, viii474.	1.2	0
40	Abstract LB-256: Impact of metformin on progression-free survival in diabetic patients with advanced pancreatic neuroendocrine tumors (pNETs) receiving everolimus and/or somatostatin analogues: A sensitivity analysis of the PRIME-NET (pancreatic multicentric, retrospective, italian metformin) study. , 2017, , .		0